Hematology

Program Director: Ramaswamy Govindan, MD

Faculty:

Andre Goy, MD, MPH Hagop M. Kantarjian, MD Sagar Lonial, MD

Robert S. Mocharnuk, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss the roles of bortezomib and lenalidomide in first-line treatment of multiple myeloma
• Describe the data on the use of tyrosine kinase inhibitors in leukemia and myelofibrosis
• Summarize the approaches taken to improve on standard rituximab-CHOP in diffuse large B-cell lymphomas
• Explain the rationale for mTOR and histone deacetylase inhibition in aggressive lymphomas
• Relate the latest data on azacitidine in myelodysplastic syndromes

Topics covered include:

• Lenalidomide Plus Low-Dose Dexamethasone Safe and Highly Active With or Without ASCT in Newly Diagnosed MM
• Bortezomib, Dexamethasone Induction Therapy Yields Superior Response Rates Compared With Vincristine, Doxorubicin, Dexamethasone Before ASCT in MM Patients
• High Response Rate With Induction Pegylated Liposomal Doxorubicin/Dexamethasone Followed by ASCT and Lenalidomide/Prednisone Consolidation in Older MM Patients
• Addition of Bortezomib to Lenalidomide in Relapsed/Refractory MM Patients
• Bosutinib Treatment of Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Imatinib and Other Tyrosine Kinase Inhibitors
• Novel JAK Inhibitor INCB018424 Active in Patients With Primary Myelofibrosis and Postpolycythemia Vera/Essential Thrombocythemia Myelofibrosis
• Addition of Imatinib to Hyper-Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone May Improve Outcomes in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
• Frontline Subcutaneous Low-Dose Alemtuzumab in Elderly Chronic Lymphocytic Leukemia Patients With Chromosome 17p Deletion
• Complete Remission Not Required for Azacitidine Survival Benefit in Patients With Higher-Risk Myelodysplastic Syndromes
• Interim Phase II Data Show Epratuzumab Added to Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Safe and Highly Effective as Initial Therapy for Diffuse Large B-Cell Lymphomas
• Dose-Dense R-CHOP-14 in Elderly Patients With Poor-Prognosis DLBCL
• Lenalidomide Demonstrates Activity in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma
• Improved Progression-Free Survival With Temsirolimus vs Investigator’s Choice in Relapsed/Refractory Mantle Cell Lymphoma
• HDAC Inhibitor MGCD0103 Active In Relapsed/Refractory Hodgkin’s Lymphoma
• Conclusion